Kusiak Aleksander, Bednarek Agnieszka, Moskal Paweł, Drożdż Tomasz, Jankowski Piotr, Czarnecka Danuta
Przegl Lek. 2016;73(11):821-3.
Cancer appears to be a major noncardiovascular factor affecting morbidity and mortality of heart failure (HF) patients. Risk of developing cancer seems to increase over time. It is well documented that patients with cancer treated with chemiotherapy are at risk of developing HF and therefore they should be screened for HF on regular basis. There is limited data whether the opposite should be done, namely routinely screen each HF patient for cancer.
We hypothesized that in HF patients cancer might be responsible for some symptoms that are incorrectly diagnose as HF related.
The data from “Renal Denervation in Patients With Chronic Heart Failure and Resynchronization Therapy” study of 18 patients (22% women) aged 73.2 (±9.1 years) with HF in NYHA Class II-IV and resynchronization pacemaker implanted according to current ESC guideliness at least 6 months earlier were analyzed. Patients had symptoms of heart failure despite optimal HF therapy including pharmacotherapy and CRT. Medical history including current symptoms of HF was taken, patients’ demographics and vital signs were assessed. Diagnostic tests in the study group included echocardiography, abdominal CT scan and laboratory tests.
Only in 5 patients CT scan did not show any abnormalities. Renal cysts were present in 5 patients, adrenal glands adenomas were observed in 3 patients and both changes were present in 1 patient. Tumors suspected of malignancy were diagnosed in 4 patients - 2 had a tumor in adrenal glands, 1 had kidney tumor and 1 had tumors both in kidney and adrenal gland. All patients with malignancy were directed for further oncological evaluation.
Considering the complex physiology of HF, there is possibility that some HF related mechanisms might trigger cancer development and presence of cancer may aggrevate the symptoms of HF. One should consider evaluation of HF patients on optimal medical therapy, yet still symptomatic to identify some common forms of cancer.
癌症似乎是影响心力衰竭(HF)患者发病率和死亡率的一个主要非心血管因素。患癌风险似乎会随着时间的推移而增加。有充分的文献记载,接受化疗的癌症患者有发生HF的风险,因此应定期对他们进行HF筛查。关于是否应采取相反做法,即对每位HF患者进行常规癌症筛查,数据有限。
我们假设在HF患者中,癌症可能是一些被错误诊断为与HF相关的症状的病因。
分析了“慢性心力衰竭患者的肾去神经支配与再同步治疗”研究中的数据,该研究纳入了18例患者(22%为女性),年龄为73.2(±9.1岁),NYHA心功能分级为II-IV级,且至少在6个月前根据当前欧洲心脏病学会(ESC)指南植入了再同步起搏器。尽管接受了包括药物治疗和心脏再同步治疗(CRT)在内的最佳HF治疗,患者仍有心力衰竭症状。记录了患者的病史,包括当前的HF症状,评估了患者的人口统计学特征和生命体征。研究组的诊断检查包括超声心动图、腹部CT扫描和实验室检查。
只有5例患者的CT扫描未显示任何异常。5例患者存在肾囊肿,3例患者观察到肾上腺腺瘤,1例患者同时存在这两种病变。4例患者被诊断出疑似恶性肿瘤——2例肾上腺有肿瘤,1例有肾肿瘤,1例肾和肾上腺都有肿瘤。所有恶性肿瘤患者均被转至进一步的肿瘤学评估。
考虑到HF复杂的生理学机制,存在一些与HF相关的机制可能触发癌症发生的可能性,而癌症的存在可能会加重HF症状。对于接受最佳药物治疗但仍有症状的HF患者,应考虑进行评估,以识别一些常见的癌症类型。